36 active not recruiting. 36 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Active not recruiting 36 |
| Phase 1 | 6 | Active not recruiting 6 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) nab-Sirolimus, Fulvestrant - Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Active not recruiting | University of Oklahoma | 37 | 2024-12-26 | 2026-06-12 |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) Belzutifan, Fulvestrant, Everolimus - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 120 | 2024-11-27 | 2026-08-28 |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. futibatinib, futibatinib, fulvestrant - Advanced/Metastatic Cancer | Phase 2 / Phase 3 | Active not recruiting | Taiho Oncology, Inc. | 15 | 2024-10-01 | 2026-07-28 |
| A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer Alpelisib Pill, Fulvestrant injection - Endometroid Endometrial Cancer | Phase 2 | Active not recruiting | GOG Foundation | 51 | 2024-09-11 | 2026-07-30 |
| Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy Letrozole, Anastrozole, Exemestane - HR+/HER2- Advanced/Metastatic Breast Cancer | Phase 2 | Active not recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 78 | 2024-02-29 | 2025-05-04 |
| A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus - Advanced or Metastatic Breast Cancer | Phase 2 | Active not recruiting | Pfizer | 333 | 2024-01-09 | 2026-08-20 |
| A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer Lenvatinib, Pembrolizuma, Fulvestrant - Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-12-29 | 2026-09-28 |
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg - Metastatic Breast Cancer, ER+ Breast Cancer | Phase 2 | Active not recruiting | Royal Marsden NHS Foundation Trust | 57 | 2022-12-28 | 2026-04-14 |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. Alpelisib, Tucatinib, Fulvestrant - HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Criterium, Inc. | 40 | 2022-08-25 | 2026-03-16 |
| Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 132 | 2022-08-01 | 2025-05-14 |
| Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies Palbociclib, Cetuximab, Fulvestrant - Breast Cancer, Head and Neck Cancer | Phase 2 | Active not recruiting | Pfizer | 35 | 2022-07-07 | 2026-09-09 |
| SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) Alpelisib 150 MG Oral Tablet [Piqray], Fulvestrant - Neoplasm, Breast, Congenital, Familial and Genetic Disorders | Phase 2 | Active not recruiting | Borstkanker Onderzoek Groep | 130 | 2022-06-02 | 2026-05-22 |
| CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer CFI-402257, Fulvestrant - Advanced Solid Tumor, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Treadwell Therapeutics, Inc | 44 | 2022-05-27 | 2025-05-18 |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) Pyrotinib Maleate, Dalpiciclib Isethionate Tablets, Inetetamab - Breast Neoplasms | Phase 2 | Active not recruiting | Henan Cancer Hospital | 120 | 2022-05-20 | 2026-10-16 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Ketogenic Diet, Low Carbohydrate Diet, Alpelisib - Breast Cancer, Breast Cancer Stage IV | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2021-10-08 | 2026-08-11 |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Alpelisib, Fulvestrant, Aromatase inhibitor - Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | Active not recruiting | Marina N Sharifi | 44 | 2021-02-12 | 2026-01-02 |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) Palbociclib, Fulvestrant, Adjuvant Therapy - Breast Cancer | Phase 2 | Active not recruiting | Criterium, Inc. | 70 | 2021-02-09 | 2026-10-15 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer Alpelisib, Fulvestrant, Placebo - Breast Neoplasms | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 69 | 2021-01-20 | 2026-09-18 |
Showing 20 of 36. Sign in to see all of them.
Breast Neoplasms (25) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Recurrence (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Genetic Diseases, Inborn (1) · Head and Neck Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urologic Neoplasms (1) · Uterine Cervical Neoplasms (1) · Uterine Neoplasms (1)
Pfizer (3) · Criterium, Inc. (2) · Hoffmann-La Roche (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · Borstkanker Onderzoek Groep (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · GOG Foundation (1) · Henan Cancer Hospital (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (27) · China (9) · United Kingdom (9) · South Korea (8) · Argentina (5) · Taiwan (5) · Canada (4) · France (4) · Germany (4) · Spain (4) · Thailand (4) · Ukraine (4) · Australia (3) · Belgium (3) · Brazil (3)
Sherry Shen, MD (2) · Alicia Okines (1) · Amir A. Jazaeri, MD (1) · Anthony D Elias, MD (1) · Christina Washington, MD (1) · Elena Shagisultanova, MD (1) · Erica L Mayer, MD MPH (1) · Frances Valdes-Albini, MD (1) · Inge I.R. Konings, MD PhD (1) · Jessica Tao, MD (1) · Joanne Mortimer (1) · Lajos Pusztai, MD (1)
PMID 32035020, PMID 33757987, PMID 34217908, PMID 35671774, PMID 37751561, PMID 38305868, PMID 38513188, PMID 38537155, PMID 38729567, PMID 39368973, PMID 39476340, PMID 39481395, PMID 39825152, PMID 40454641, PMID 40986529
2023 (3), 2019 (2), 2018 (1), P30CA033572 (1)